Trial Profile
Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
- Focus Therapeutic Use
- Acronyms CHOP-OR
- 27 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 27 May 2015 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 07 Jan 2015 Accrual to date is 107% according to United Kingdom Clinical Research Network record.